Accession PRJCA000214
Title Abraxane, the Nanoparticle Formulation of Paclitaxel can Induce Drug Resistance by Up-regulation of P-gp
Relevance Medical
Data Types Transcriptome or Gene expression
Organisms Homo sapiens
Description Abraxane, a nanoparticle (NP) formulation of paclitaxel (PTX), has been demonstrated to be more effective than Taxol, the small molecule formulation, for the treatment of breast cancer and non-small cell lung cancer (NSCLC). It was reported that Abraxane existed in plasma as particles with the size of ~10 nm. NPs get in and out of the cells by endocytosis and exocytosis, whereas small molecules by diffusion and efflux. It is intriguing to know whether the improved pharmaceutical performance is related to the “too-big-to-be-pumped-out” phenomenon. Here we established an Abraxane-resistant NSCLC cell line A549/Abr and compared its transcriptomes with that of the Abraxane-sensitive parental cell line by RNA-Seq technology. To our surprise, the most significantly up-regulated genes were ABC transporters, the common efflux pump for small molecules. We further found that the ABCB1 inhibitor Verapamil reversed the drug resistance and confirmed the important role of ABCB1 in Abraxane resistance.
Sample scope Monoisolate
Release date 2016-03-24
Publication
PubMed ID Article title Journal name DOI Year
26182353 Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp. PloS One 10.1371/journal.pone.0131429 2015
Accessions in other database
Accession Database name
GSE56742 NCBI
Submitter Yadong    Yang  (yangyd@big.ac.cn)
Organization Beijing Institute of Genomics
Submission date 2016-03-24

Project Data

Resource name Description
BioSample (5) -
SAMC005919 A549_R_100
SAMC005918 A549-R-0
SAMC005917 A549-P-100
SAMC005916 A549-P-2
SAMC005915 A549-P-1
GSA (1) -
CRA000089 CRA_89
-